- Home
- AMRN vs IMMP Comparison
AMRN vs IMMP Comparison
Compare AMRN & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- IMMP
- Stock Information
- Founded
- AMRN 1989
- IMMP 1987
- Country
- AMRN Ireland
- IMMP Australia
- Employees
- AMRN N/A
- IMMP N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- IMMP Health Care
- Exchange
- AMRN Nasdaq
- IMMP Nasdaq
- Market Cap
- AMRN 189.2M
- IMMP 211.1M
- IPO Year
- AMRN 1993
- IMMP N/A
- Fundamental
- Price
- AMRN $9.11
- IMMP $1.54
- Analyst Decision
- AMRN Sell
- IMMP Buy
- Analyst Count
- AMRN 2
- IMMP 2
- Target Price
- AMRN $7.00
- IMMP $8.50
- AVG Volume (30 Days)
- AMRN 103.6K
- IMMP 85.9K
- Earning Date
- AMRN 04-30-2025
- IMMP 04-29-2025
- Dividend Yield
- AMRN N/A
- IMMP N/A
- EPS Growth
- AMRN N/A
- IMMP N/A
- EPS
- AMRN N/A
- IMMP N/A
- Revenue
- AMRN $228,614,000.00
- IMMP $3,019,249.00
- Revenue This Year
- AMRN N/A
- IMMP N/A
- Revenue Next Year
- AMRN $5.18
- IMMP $20.28
- P/E Ratio
- AMRN N/A
- IMMP N/A
- Revenue Growth
- AMRN N/A
- IMMP 24.11
- 52 Week Low
- AMRN $7.00
- IMMP $1.32
- 52 Week High
- AMRN $20.60
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- AMRN 48.45
- IMMP 42.49
- Support Level
- AMRN $8.32
- IMMP $1.44
- Resistance Level
- AMRN $10.06
- IMMP $1.56
- Average True Range (ATR)
- AMRN 0.87
- IMMP 0.12
- MACD
- AMRN 0.15
- IMMP -0.00
- Stochastic Oscillator
- AMRN 60.40
- IMMP 39.29
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.